A civil jury in Ireland finds that mixed martial arts fighter Conor McGregor assaulted a woman in a hotel. (CORRECTS: A previous APNewsAlert misstated the claim the jury found him liable for.)New pro-European coalition approved in Romania amid period of political turmoil

TO REPORT SCORES Coaches or team representatives, please report results as soon as possible after games by emailing sports@caledonian-record.com . Please submit with a name/contact number. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.Marvell Technology, Inc. Declares Quarterly Dividend PaymentStock market today: Wall Street ends mixed after a bumpy week

Meta to build $10 billion AI data center in LouisianaStock market today: Wall Street rises at the start of a holiday-shortened week

Major stock indexes we mixed on Wall Street in afternoon trading Monday, marking a choppy start to a holiday-shortened week. The S&P 500 rose 0.6%. The Dow Jones Industrial Average slipped 21 points, or 0.1% as of 2:22 p.m. Eastern time. The tech-heavy Nasdaq composite rose 1%. Gains in technology and communications stocks helped outweigh losses in consumer goods companies and elsewhere in the market. Semiconductor giant Nvidia, whose enormous valuation gives it an outsize influence on indexes, rose 3.6%. Broadcom jumped 5.7% to also help support the broader market. Walmart fell 2.2% and PepsiCo slid 1.3%. Japanese automakers Honda Motor and Nissan said they are talking about combining in a deal that might also include Mitsubishi Motors. U.S.-listed shares in Honda jumped 12.1% , while Nissan fell 0.9%. Eli Lilly rose 3.3% after announcing that regulators approved Zepbound as the first and only prescription medicine for adults with sleep apnea. Department store Nordstrom fell 1.7% after it agreed to be taken private by Nordstrom family members and a Mexican retail group in a $6.25 billion deal. The Conference Board said that consumer confidence slipped in December. Its consumer confidence index fell back to 104.7 from 112.8 in November. Wall Street was expecting a reading of 113.8. The unexpectedly weak consumer confidence update follows several generally strong economic reports last week. One report showed the overall economy grew at a 3.1% annualized rate during the summer, faster than earlier thought. The latest report on unemployment benefit applications showed that the job market remains solid. A report on Friday said a measure of inflation the Federal Reserve likes to use was slightly lower last month than economists expected. Worries about inflation edging higher again had been weighing on Wall Street and the Fed. The central bank just delivered its third cut to interest rates this year, but inflation has been hovering stubbornly above its target of 2%. It has signaled that it could deliver fewer cuts to interest rates next year than it earlier anticipated because of concerns over inflation. Expectations for more interest rate cuts have helped drive a 25% gain for the S&P 500 in 2024. That drive included 57 all-time highs this year. Inflation concerns have added to uncertainties heading into 2025, which include the labor market's path ahead and shifting economic policies under an incoming President Donald Trump. "Put simply, much of the strong market performance prior to last week was driven by expectations that a best-case scenario was the base case for 2025," said Brent Schutte, chief investment officer at Northwestern Mutual Wealth Management Company Treasury yields rose in the bond market. The yield on the 10-year Treasury rose to 4.59% from 4.53% late Friday. European markets were mostly lower, while markets in Asia gained ground. Wall Street has several other economic reports to look forward to this week. On Tuesday, the U.S. will release its November report for sales of newly constructed homes. A weekly update on unemployment benefits is expected on Thursday. Markets in the U.S. will close at 1 p.m. Eastern on Tuesday for Christmas Eve and will remain closed on Wednesday for Christmas.MEDIROM Healthcare Technology‘s Subsidiary, MEDIROM MOTHER Labs, Raises an Aggregate Total of ...

Jennison Associates LLC bought a new stake in shares of BridgeBio Pharma, Inc. ( NASDAQ:BBIO – Free Report ) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 30,119 shares of the company’s stock, valued at approximately $767,000. Other large investors have also bought and sold shares of the company. Bfsg LLC lifted its holdings in BridgeBio Pharma by 175.6% in the 2nd quarter. Bfsg LLC now owns 1,240 shares of the company’s stock valued at $31,000 after acquiring an additional 790 shares during the last quarter. Headlands Technologies LLC bought a new stake in shares of BridgeBio Pharma in the 2nd quarter worth approximately $48,000. Values First Advisors Inc. bought a new stake in shares of BridgeBio Pharma in the 3rd quarter worth approximately $57,000. CWM LLC lifted its stake in BridgeBio Pharma by 132.9% during the third quarter. CWM LLC now owns 3,442 shares of the company’s stock valued at $88,000 after purchasing an additional 1,964 shares during the last quarter. Finally, Amalgamated Bank boosted its holdings in BridgeBio Pharma by 24.7% during the second quarter. Amalgamated Bank now owns 4,863 shares of the company’s stock worth $123,000 after buying an additional 962 shares in the last quarter. Institutional investors own 99.85% of the company’s stock. BridgeBio Pharma Stock Performance BridgeBio Pharma stock opened at $23.42 on Friday. BridgeBio Pharma, Inc. has a twelve month low of $21.62 and a twelve month high of $44.32. The firm has a market cap of $4.43 billion, a PE ratio of -9.72 and a beta of 1.09. The firm’s 50 day moving average price is $24.96 and its two-hundred day moving average price is $26.25. Analysts Set New Price Targets Get Our Latest Analysis on BridgeBio Pharma Insider Activity In related news, CEO Neil Kumar sold 27,389 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $22.41, for a total value of $613,787.49. Following the completion of the sale, the chief executive officer now owns 4,897,443 shares of the company’s stock, valued at approximately $109,751,697.63. The trade was a 0.56 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link . Also, major shareholder Genetic Disorder L.P. Kkr sold 5,800,000 shares of the firm’s stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $25.75, for a total transaction of $149,350,000.00. Following the transaction, the insider now directly owns 25,260,971 shares in the company, valued at approximately $650,470,003.25. The trade was a 18.67 % decrease in their position. The disclosure for this sale can be found here . Insiders have sold a total of 5,831,545 shares of company stock worth $150,056,923 in the last ninety days. Corporate insiders own 24.66% of the company’s stock. About BridgeBio Pharma ( Free Report ) BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. Featured Stories Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter .

Miley Cyrus Teases A New Era For 2025 In A Reflective, Year-Ending MessageRussell Martin takes responsibility for Southampton's defensive errors: 'That is on me'Pals' 'panic' as Tulisa 'disappears' from Aussie hotel after I'm a Celebrity exit